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Table 1. Summary of aGVHD severity and treatment response (N549)
Budesonide Single
Agent (N520)
Systemic
Corticosteroids (N525)
No Therapy or
Topical Steroids (N54)
Total
(N549)
N (%) Organs Involved
Skin Alone - 5 (20%) 3 (75%) 8 (16%)
GI Alone 9 (45%) 2 (8%) - 11 (23%)
Liver Alone - 1 (4%) 1 (25%) 2 (4%)
Skin/GI 9 (45%) 10 (40%) - 19 (39%)
GI/Liver 1 (5%) 3 (12%) - 4 (8%)
Skin/GI/Liver 1 (5%) 5 (20%) - 5 (10%)
N (%) Grade aGVHD
II 20 (100%) 5 (20%) 3 (75%) 28 (57%)
III - 15 (60%) 1 (25%) 16 (33%)
IV - 5 (20%) - 5 (10%)
N (%) Day 28 Treatment Response
CR/PR 7(35%)/9(45%) 8(32%)/12(48%) 3(75%)/1(25%) 40 (82%)
hPR 4 (20%) 5 (20%) - 9 (18%)
N (%) Day 56 Treatment Response
CR/PR 10(50%)/7(35%) 7(28%)/13(52%) 4 (100%)/ 0 41 (84%)
hPR 3 (15%) 5 (20%) - 8 (16%)
Poster Session II S343inhibitor and mycophenolate mofetil. Forty-nine patients developed
grade II-IV aGVHD by day 100 for a cumulative incidence of 50%
(95%CI:40-60) grade II-IV and 26% (95%CI:16-35) grade III-IV,
respectively. The median time of aGVHD onset was 39 days (range
14-99). Organs most commonly affected were skin/ GI (39%), GI
alone (23%), and skin alone (16%). Single agent budesonide was
used for the treatment of 20 patients with initial grade II GI aGVHD
(Table 1). Complete or partial responses (CR/PR) were observed by
day 28 in the majority (n5 16, 80%), which were maintained at day
56. Notably, only 3 of 20 budesonide patients required salvage with
systemic corticosteroids (2 responded, 1 progressed). Twenty-five
patients with predominantly grade III-IV aGVHD received systemic
corticosteroids from the outset of therapy (Table 1). CR or PR was
obtained in 80% by day 56. With a median follow-up of 24 months
(range 4.5-60.5), the 1-year cumulative incidence of ongoing late
acute or chronic GVHD was 35% (95%CI:26-45), and the 1-year
progression-free survival is 65% (95%CI:56-75). Seven patients
have died of GVHD, 2 patients initially treated with budesonide,
and 5 with systemic corticosteroids. We conclude that double unit
CBT is associated with a significant incidence of grade II-IV
aGVHDand new strategies for prophylaxis are warranted.However,
a significant number of patients with grade II GI aGVHD can be
treated successfully with budesonide alone, and this approach war-
rants prospective investigation. Finally, new therapies are needed
for CBT recipients with more severe aGVHD.530
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cGVHD is the most serious and common long-term complication
of this allogeneic transplantation, occurring in 30-70% of patients
surviving more than 100 days. cGVHD is associated with a high de-
gree of morbidity and mortality and remains a major cause of late
death. Initial therapy involves systemic corticosteroids which can
contribute to further complications. In cases where steroids are inef-
fective or poorly tolerated, effective therapeutic options are limited.
Anecdotal reports of myeloma patients treated with bortezomib after
transplantation have shown improvement in cGVHD.
We have begun a trial of bortezomib in patients with steroid-re-
fractory cGVHD. Patients receive 1.6 mg/m2 q wk x 4 followed by
one week of rest, for up to six cycles. To date 9 patients have beenentered on trial and 5 have completed between 2 and 4 cycles. The
treatment has been well tolerated with no grade 3 or higher adverse
events (AE). AE have been grade 1-2 nausea (3), grade 1-2 diarrhea
(6) grade 1-2 fatigue (4), one grade 2 transient neuropathy has
been reported. There have been 3 treatment delays (1 patient) and
dose reduction due to decreased hemoglobin and one due to tran-
sient neuropathy.
Subjective improvement has reported in 6 of the first 8 patients,
Improvement in general well-being has been noted as early as the
first treatment. Two patients have had improvement in severe long
standing sclerotic changes, including the ability to extend fingers
that had long been contracted. Average Rodnan scores on 5 patients
with sclerosis completing 2 or more cycles of therapy decreased from
(3169.6 to 13.867.5) One patient with non-healing suppurating le-
sions of his lower extremities has shownmarked healing, another has
significant decrease in chronic diarrhea.
Weekly bortezomib for cGVHD appears to be well tolerated and
results in early improvement in long standing refractory disease. Our
plan is to enroll twenty-five patients to determine if these encourag-
ing findings are sustainable.531
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Background: The great variability in the diagnosis of chronic
GVHD and the long period required to complete clinical trials
S344 Poster Session IIdue to slow patient accrual are, in part, responsible for the slow prog-
ress in this area. Participation of international centers in multicenter
clinical trials is needed. Towards this effort, a Brazil-Seattle chronic
GVHD consortiumwas established to conduct collaborative studies,
which included a survey of chronic GVHD after allogeneic hemato-
poietic cell transplantation (allo-HCT) performed in Brazil.
Method:Thirty-six transplant services registered with the Brazilian
Society of Bone Marrow Transplantation were invited to participate
in a web-based survey containing 36 questions about routines and
major outcomes of allo-HCTs performed in 2008.
Results: Seventeen (47%) centers performed allo-HCTs in 2008
and completed the survey between May and September 2010. The
17 responding centers have been performing allogeneic transplants
for a median of 16 (range, 7-31) years. Among the 17 centers, theme-
dian number of allogeneic transplants reported in 2008 was 21
(range, 5-116), of which 91%were from a related donor. Themedian
number of adult allo-HCTs was 16 (range, 2-84) and the median
numbers of pediatric allo-HCTs was 3 (range, 0-51). Of the reported
510 allo-HCTs in 2008, near 60% were performed at four centers.
For classification of chronic GVHD, 50% reported using the NIH
criteria, 37% the Seattle revised classification and 12% both criteria.
Eighty-eight percent of the centers reported performing chronic
GVHD screening evaluation between days 80 -100 after HCT.
Three centers reported seeing . 12 new cases of chronic GVHD
in one year, 5 reported seeing 6-12 patients, and 9 centers reported
seeing\ 6 new cases. The overall disease-free survival (DFS) rates
at 100 days were . 75% (7 centers), 50-75% (9 centers) and 26-
50% (1 center). The overall DFS at 1-year was 50-75% as reported
by 13 centers and was 26-50% as reported by 4 centers. The table
summarizes the types of primary and secondary treatments reported
for chronic GVHD.
Conclusion:The variability in diagnosis and treatment of chronic
GVHD in Brazilian Centers is similar to that previously reported
by American and European centers. The Brazil-Seattle chronic
GVHD consortium network exemplifies the feasibility of collabo-
rative research across the international borders of Western hemi-
sphere and offers new opportunities for future collaborative
studies.
Table 1. Chronic GVHD therapy reported
Therapy First Line (%*) Second Line (%*)Steroid 1mg/kg/day 100 19
Cyclosporine 75 44
Tacrolimus 25 31
Mycophenolate mofetil - 94
PUVA - 62
ECP (photopheresis) - 44
Thalidomide - 44
Azathioprine - 25
Sirolimus - 12
Anti-CD20 antibody - 12*Frequency of therapy prescribed.532
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Background: While genital chronic graft versus host disease
(cGVHD) has become better characterized, genital acute GVHD
(aGVHD), a rarer entity, remains poorly understood.
Objective: To describe genital aGVHD in a cohort with genital
GVHD.
Methods: A cohort of 68 women were diagnosed with genital
GVHD. Among these 68, some with gynecologic symptoms were as-
sessed within 100 days post-transplant as part of transplantation pro-tocols. We evaluated time from hematopoietic cell transplant
(HCT), other GVHD manifestations, gynecologic history, vulvar/
vaginal findings, clinical course and treatment to better characterize
genital aGVHD.
Results: Of 68 patients, 6 were diagnosed with genital GVHD
prior to 100 days post-HCT (median 79: range 14-92). Of these
6 patients, 4 were diagnosed with aGVHD involving the skin
(2) or skin and gastrointestinal tract (2) prior to diagnosis of gen-
ital aGVHD (median 29.5: range 6-54 days). One other patient
presented with genital aGVHD the day before skin aGVHD
was diagnosed. Only 1 genital aGVHD patient had no other tissue
site of involvement. Only 1 patient had an early donor lymphocyte
infusion, which was administered at 42 days post-HCT; this pa-
tient was diagnosed with genital aGVHD at 92 days post-HCT.
5 of 6 patients (83.3%) had Grade II genital GVHD at presenta-
tion (as defined by Stratton et al 2009), while one patient
presented with Grade I disease. These Grade II patients were
treated with topical clobetasol or topical tacrolimus. Of these 5
treated patients, 4 returned for follow-up care. Over a one-year
observation interval, one patient had a complete response, one pa-
tient had a partial response, and two patients progressed from
Grade II to Grade III disease. One patient with vaginal synechiae
was treated with an estradiol vaginal ring, with complete response
observed.
Conclusions: Our findings indicate that genital GVHD can occur
before 100 days after allogeneic HCT. Considering that 5 of 6
(83%) affected patients in this series had acuteGVHDof other organ
systems, gynecologic issues should be included in the GVHD evalu-
ation of female transplant patients. Finally, because genital aGVHD
was, in general, amenable to topical treatments, our findings offer
hope that with appropriate diagnosis and intervention, genital
aGVHD can be effectively treated to improve the quality of life of
female transplant survivors.
Support: Intramural Program, ETIB/NCI, POB/NCI, PRAE/
NICHD.533
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Mycophenolate mofetil (MMF) is an ester prodrug of mycophe-
nolic acid (MPA) which has been used successfully in the prevention
and treatment of acute graft-versus-host-disease (aGVHD). Previ-
ous pharmacokinetics (PK) studies have shown low MPA exposure
in BMT recipients, especially in the period following conditioning
therapy, which is associated with inferior transplant outcomes. Mul-
tiple strategies, including empiric fixed-dose-escalation or higher
dose per kg body weight, have failed to achieve consistent target
MPA exposure. Attempts at giving MMF as short-infusion doses
have been unsuccessful inmaintaining desired trough concentrations
(Ctrough) of MPA, especially in pediatric BMT patients. We hy-
pothesized that a PK-based dosing strategy using a novel continuous
infusion of MMF will be able to achieve and maintain target MPA
exposure. The primary aim of this pilot study is to evaluate the safety
and feasibility of this approach.
Continuous infusion MMF was evaluated in 5 pediatric patients
undergoing unrelated donor myeloablative transplant between
July, 2009 and June, 2010. Mean age was 8.5 y (2-17 y) (4 F, 1
M). Patient diagnoses were MDS (2), ALL in CR2, Kostmann
syndrome, and congenital erythropoietic porphyria. Three pa-
tients received MMF for GVHD prophylaxis and two for treat-
ment of severe aGVHD. In all cases, total MPA Ctrough levels
remained \ 1 mcg/mL with intermittent IV dosing (15 mg/kg/
dose q8 hourly). PK measurements on this schedule were used
to estimate MPA clearance in order to predict the rate of a contin-
uous infusion to maintain total MPA steady-state concentrations
(Css) between 2.5-5 mcg/mL. Rates of infusion used ranged
